Colombia |
dc.creatorPan, Xiaoqi
dc.creatorDong, Lan
dc.creatorYang, Lian
dc.creatorChen, Dayi
dc.creatorPeng, Cheng
dc.date.accessioned2020-07-31T20:59:13Z
dc.date.accessioned2022-09-23T18:17:01Z
dc.date.available2020-07-31T20:59:13Z
dc.date.available2022-09-23T18:17:01Z
dc.date.created2020-07-31T20:59:13Z
dc.identifier0168-1702
dc.identifierhttps://doi.org/10.1016/j.virusres.2020.198057
dc.identifierhttp://hdl.handle.net/20.500.12010/11503
dc.identifierhttps://doi.org/10.1016/j.virusres.2020.198057
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3498365
dc.description.abstractThe fight against the novel coronavirus pneumonia (namely COVID-19) that seriously harms human health is a common task for all mankind. Currently, development of drugs against the novel coronavirus (namely SARSCoV-2) is quite urgent. Chinese medical workers and scientific researchers have found some drugs to play potential therapeutic effects on COVID-19 at the cellular level or in preliminary clinical trials. However, more fundamental studies and large sample clinical trials need to be done to ensure the efficacy and safety of these drugs. The adoption of these drugs without further testing must be careful. The relevant articles, news, and government reports published on the official and Preprint websites, PubMed and China National Knowledge Infrastructure (CNKI) databases from December 2019 to April 2020 were searched and manually filtered. The general pharmacological characteristics, indications, adverse reactions, general usage, and especially current status of the treatment of COVID-19 of those potentially effective drugs, including chemical drugs, traditional Chinese medicines (TCMs), and biological products in China were summarized in this review to guide reasonable medication and the development of specific drugs for the treatment of COVID-19.
dc.publisherVirus Research - Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectChemical drugs
dc.subjectTraditional Chinese medicines
dc.subjectBiological products
dc.titlePotential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China


Este ítem pertenece a la siguiente institución